Free tool
FAERS Monitor: Korsuva
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214916 or its brand name (Korsuva, Difelikefalin Acetate). Reports on generic versions are filed under their own applications.
Reports
413
Serious
297
72% of reports
Hospitalization
124
Death reported
64
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness45
- somnolence40
- fall35
- death30
- drug ineffective24
- mental status changes23
- confusional state19
- asthenia18
- nausea18
- off label use17
- pruritus17
- hallucination16
- blood pressure decreased14
- drug reaction with eosinophilia and systemic symptoms14
- altered state of consciousness11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 61 |
| 2023 | 124 |
| 2024 | 83 |
| 2025 | 102 |
| 2026 | 43 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,746 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mental status changesSignal | 23 | 42.2 | 28.4 | 885 |
| drug reaction with eosinophilia and systemic symptomsSignal | 14 | 27.7 | 16.6 | 335 |
| altered state of consciousnessSignal | 11 | 25.9 | 14.4 | 239 |
| hallucinationSignal | 16 | 10.8 | 6.7 | 133 |
| blood pressure decreasedSignal | 14 | 10.7 | 6.4 | 114 |
| somnolenceSignal | 40 | 10.1 | 7.5 | 323 |
| confusional stateSignal | 19 | 6.0 | 3.9 | 75 |
| fallSignal | 35 | 5.4 | 3.9 | 122 |
| dizzinessSignal | 45 | 4.6 | 3.5 | 126 |
| astheniaSignal | 18 | 2.4 | 1.6 | 14 |
| pruritusSignal | 17 | 2.3 | 1.4 | 11 |
| death | 30 | 1.8 | 1.3 | 10 |
| nausea | 18 | 1.2 | 0.7 | 0 |
| off label use | 17 | 1.0 | 0.6 | 0 |
| drug ineffective | 24 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.